Strategic Acquisition Basepaws is now part of Zoetis, positioning it as a core asset in the precision animal health portfolio. Sales teams can leverage Zoetis’ extensive veterinary channel and global reach to cross-sell advanced genetics and microbiome testing capabilities to veterinarians and pet owners.

Expanded D2C Potential With prior launches of at home tests and plans for new direct-to-consumer dog DNA tests, there is a clear opportunity to market consumer-friendly genetic health tests through popular channels like Amazon and Basepaws’ website, tapping into pet owners seeking proactive wellness insights.

Veterinary Collaboration Recent tools for veterinary teams and partnerships with veterinary networks suggest upside in B2B sales to clinics and hospitals. Focus outbound messaging on enabling vets with genetic and oral microbiome screening tools to enhance preventive care and client engagement.

Integrated Health Platform The combination of host genetics and microbiome data supports a holistic health platform. Opportunities exist to upsell bundled testing services, data-driven risk alerts, and proactive care programs to veterinary practices and pet parents seeking early detection capabilities.

Global Growth Path Zoetis acquisition creates a springboard for scaling beyond LA or US markets. Explore partnerships and channel expansion in regions where Zoetis has strong presence, aligning product messaging with regulatory and reimbursement landscapes to drive adoption.